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Summary: Sulphadimidine acetylation studies were un-dertaken in 103 patients, 52 of whom had been clas-
sified as slow and 51 as rapid inactivators of isoniazid by
a standard microbiological assay method. Each patient
received sulphadimidine by mouth in a dose of 44
mg./kg. body weight, and free and total sulphadimidine
were estimated in blood and urine collected at six hours.
The findings suggest that patients may be classified as
slow inactivators of isoniazid if the proportion of ace-
tylated sulphadimidine (total minus free) is (a) less than
25% in blood or (b) less than 70% in urine. The
sulphadimidine test is easy to perform and the result is
available the same day; urine specimens for the test can
be stored at room temperature for over a week without
any loss of drug.
Introduction
Several investigators have shown that the rate of inactivation
of isoniazid depends on the rate of its acetylation (Evans and
White, 1964; Peters, Miller, and Brown, 1965), and that indi-
viduals can be broadly classified as slow or rapid inactivators
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2(Knight, Selin, and Harris, 1959; Evans, Manley, and
McKusick, 1960; Jenne, 1960; Sunahara, Urano, and Ogawa,
1961). Until recently the determination of the rate of inactiva-
tion had little practical value in the chemotherapy of pulmon-
ary tuberculosis, since the rate was of little or no prognostic
importance with daily regimens (Harris, 1959, 1961; Selkon
et al., 1961; Schmidt, 1962; Scottish Thoracic Society, 1962;
Tuberculosis Chemotherapy Centre, Madras, 1963). With the
advent of intermittent regimens, however, the determination
of the isoniazid inactivation rate acquired much practical
importance. For instance, a recent study from this centre
showed that the response of rapid inactivators of isoniazid
to once-weekly regimens of chemotherapy is substantially
inferior to that of slow inactivators (Menon, 1968; Tuberculosis
Chemotherapy Centre, Madras, 1970).
The rate of inactivation of isoniazid is usually determined
by estimating the concentration of free isoniazid in the serum
(by microbiological or chemical methods) at a specified time
after a test dose of the drug. However, the need for collecting
blood from the patients, the instability of isoniazid in serum
during transport (Poole and Meyer, 1960; Jenne, 1961), and
the complexity of current procedures of estimation often
render determination of the isoniazid inactivation rate im-
practicable. Thus there is a need for a relatively simple
procedure.
Both isoniazid and sulphadimidine are acetylated in the liver
by similar enzymatic processes (Evans and White, 1964), and
the rate of acetylation of isoniazid closely parallels that
of sulphadimidine (Evans and White, 1964; Peters, Cordon,
and  Brown, 1965). Indeed, the determination of the
sulphadimidine acetylation rate on liver biopsy specimens has
been successfully employed for the routine classification of
isoniazid inactivation phenotypes in man (Evans, 1965). The
results are reported here of a sulphadimidine acetylation test
in urine and blood specimens to classify patients as slow or
rapid inactivators of isoniazid.
Materials and Methods
The investigations were undertaken in patients admitted to
a chemotherapy study at this centre.
Rate of Inactivation of Isoniazid.– The concentration of
isoniazid in serum four and a half hours after an intramus-
cular test dose of 3 mg./kg. body weight was determined by
microbiological assay, using a vertical diffusion method simi-
lar to that described by Lloyd and Mitchison (1964). Patients
with concentrations of 0.63 µg./ml. or more were classified as
slow inactivators of isoniazid, and those with concentrations
of less than 0.63 µg./ml. as rapid inactivators (Tuberculosis
Chemotherapy Centre, Madras, 1970).
Acetylation of Sulphadimidine.– Pure sulphadimidine
(sulphadimethylpyrimidine, sulphamethazine) in a dose of 44
mg./kg. body weight-that is, 2 g. for a 100 lb. (45.4 kg.)
patient–was given by mouth as a fine suspension in water.
Antituberculosis drugs were withheld for at least two days
before the test, and, as a check, a urine specimen was
collected before administration of sulphadimidine and tested
for acetylisoniazid (Eidus and Hamilton, 1964) and for aro-
matic amines by diazotization and final reaction with N-(1-
naphthyl) ethylenediaminedihydrochloride. Estimations of free
and total sulphadimidine in blood and urine were undertaken
by a micro-method based on the Bratton and Marshall tech-
nique (Varley, 1962), and the acetylated sulphadimidine (total
minus free) was expressed as a percentage of the total
sulphadimidine for purposes of analysis.
Results
Timing of Collection of Blood and Urine Specimens.– In
order to determine the optimal timings for the collection of
blood and urine specimens a preliminary study was
undertaken in 10 patients, five of whom were known by the
vertical diffusion method to be slow inactivators of isoniazid,
and the other five to be rapid inactivators. In this investiga-
tion blood was drawn at 3, 6, 9, and 24 hours after the test
dose, the total urine excreted during 0-3, 3-6, and 6-9 hours
was collected, and a urine specimen was obtained at 24 hours.
The findings are presented in Table I. An examination of the
individual percentages and the t values in the last column
indicates that the discrimination between slow and rapid
inactivators was (a) most efficient with the 9-hour blood speci-
men and the 6-9-hour urine collection, (b) less efficient but
nevertheless highly satisfactory with the 6-hour blood speci-
men and the 3-6 hour urine collection, and (c) much less
efficient with the other measures. On the basis of these
results, and for convenience in organization, it was decided
that both blood and urine should be collected at 6 hours in
the main study to be described below. Furthermore, to
increase the discriminative ability of the test on urine it was
decided that the patient should be asked to empty the blad-
der at 5 hours and then drink a cup. of water. The results of
the main study, conducted on 52 known slow inactivators of
isoniazid and 51 known rapid inactivators, are presented below.
4Acetylated Sulphadimidine in Blood.– The distributions of
slow and rapid inactivators of isoniazid, according to the per-
centage of acetylated sulphadimidine in blood at six hours,
are illustrated in the upper half of the Chart and summarized
in the upper half of Table II. Less than 25% of sulphadi-
midine was acetylated by 51 of 52 slow inactivators, and
26% by the remaining patient. In contrast, 25 % or more was
acetylated by 49 of 51 rapid inactivators, and 12 and 23 % by
the remaining two patients. These findings suggest that a
patient may be classified as a slow inactivator of isoniazid if
the percentage of acetylated sulphadimidine is less than 25
and as a rapid inactivator if it is 25 or more. By employing
this classification rule, agreement with the classification based
on the findings of microbiological assay of isoniazid was
obtained in 100 of 103 patients. The three discrepancies
appear to  be  due to  misclass i f icat ion by the  blood
sulphadimidine test, as t h e  c l a s s i f i c a t i o n  b y  t h e
microbiological assay of isoniazid was confirmed in all three
by the classification based on the percentage of acetylated
sulphadimidine in urine (see below).
TABLE I. – Acetylation of Sulphadimidine After an Oral Dose of 44 mg./kg. Body Weight in Five Slow and Five Rapid Inactivators of Isoniazid
                                 Slow Inactivators†     Rap
    A  B  C D
Blood . .
. .
E P
Acetylated Sulphadimidine*
Measure of
id Inact Discrimin-
ation
t ‡
Urine . . . . . . .
* Expressed as a percentage of total-that is, acetylated plus free-sulphadimidine.
‡
† Classification based on the findings of microbiological assay of isoniazid in serum (vertical diffusion method).
Difference in means between slow and rapid inactivators divided by the standard error of the difference.
6TABLE II.- Distributions of Slow and Rapid Inactivators of Isoniazid
According to Percentage of Acetylated Sulphadimidine in Blood and Urine
Classification Based on
Acetylated Microbiological Assay
sulphadimidine* of Isoniazid
Slow
Inactivator
Rapid
Inactivator
L e s s  t h a n
Blood (at 6 hours) . . 20-24. . 25-29
30 or more
Less than 60
Urine † (5-6 hours) . . .
70 or more
*Expressed as a percentage of total–that is, acetylatcd plus free-sulphadimidine.
† The specimen was missed for one patient (rapid inactivator).
Acetylated Sulphadimidine in Urine.- The findings,
illustrated in the lower half of the Chart and summarized in
the lower half of Table II, suggest that a patient may be
classified as a slow inactivator of isoniazid if the percentage
of acetylated sulphadimidine in urine at 5-6 hours is less than
70, and as a rapid inactivator if it is 70 or more. By employ-
ing this classification rule, agreement with the classification
based on the findings of microbiological assay of isoniazid
was obtained in 101 of 102 patients. The single discrepancy
(a rapid inactivator with a value of 65%) appears to be due
to a misclassification by the urine sulphadimidine test
method, as the classification by the microbiological assay of
isoniazid was confirmed in this instance by the classification
based on the percentage of acetylated sulphadimidine in
blood (see above).
Stability of Sulphadimidine in Urine.- From each of four
subjects (three slow inactivators and one rapid inactivator) a
specimen of urine was collected at six hours after a dose of
sulphadimidine. Aliquots of each specimen were stored for
nine days at 37° C., room temperature (27°-30° C.), and at
4° C., in each case with and without the addition of thymol as
a preservative. There was no evidence of change in the con-
tent of free or total sulphadimidine under any of these condi-
tions of storage (data not presented here).
Discussion
Highly satisfactory agreement has been found between the
results obtained from a well-established procedure for clas-
sifying patients as slow or rapid inactivators of isoniazid
7(microbiological assay of isoniazid in serum, employing a ver-
tical diffusion method), and from the procedures described in
this paper, which are based on estimations of acetylated
sulphadimidine in blood and in urine after an oral dose of
sulphadimidine. Thus only 3% of our patients were misclas-
sified by the blood sulphadimidine test and 1% by the urine
sulphadimidine test. These, results confirm the observations
made by Evans and White (1964) and Peters, Gordon, and
Brown (1965), in small groups of volunteers and patients, of
parallelism between isoniazid inactivation rate and sulpha-
dimidine acetylation rate.
The advantages of the sulphadimidine acetylation test are,
firstly, the method of estimation is simple, requiring only a
calorimeter or a visible range spectrophotometer, whereas
chemical methods for the estimation of isoniazid require ex-
traction procedures with organic solvents and estimation with
an ultraviolet spectrophotometer or a fluorimeter. Secondly,
the results are available on the same day, whereas a
microbiological assay of isionazid takes about two weeks.
Thirdly, specimens do not require cold storage, since, unlike
free isoniazid, sulphadimidine and its acetyl derivative are
heat stable.
Evans (1969) observed that the percentage of acetylated
sulphadimidine in serum appeared to be a better phenotypic
discriminant than the same constituent in urine. In the
present study, however, the urine test was slightly more
efficient than the blood test in discriminating between slow
and rapid inactivators of isoniazid, the measure of discrimin-
ation (t value) being 20.5 for the urine test and 15.2 for the
blood test (see Chart). Further, it is easier to obtain urine
specimens than blood specimens from patients; in practice,
therefore, the urine sulphadimidine test is preferable to the
blood test.
We are indebted to the physicians and nursing staff of the
Centre for organizing the collection of the specimens, to Miss K.
Alamelu for technical assistance, and to Dr. N. K. Menon for help
in the preparation of the paper.
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